Advertisement

Der Internist pp 420-429 | Cite as

Rezeptoren für Neurotransmitter und psychiatrische Erkrankungen

  • H. Wetzel
  • O. Benkert

Zusammenfassung

Unser gegenwärtiges Verständnis der neurobiologischen Grundlagen psychiatrischer Erkrankungen stützt sich hauptsächlich auf die Kenntnis der molekularen Wirkmechanismen der Psychopharmaka. Die Aufklärung des Angriffspunktes dieser Medikamente an bestimmten Rezeptoren und die Erforschung ihrer Auswirkungen auf die Stgnalübertragung und den Neurotransmitterstoffwechsel im Gehirn führten nicht nur zu einer Fülle neuer Erkenntnisse über neurobiochemische Regulationsmechanismen, sondern auch zu einer Reihe von Hypothesen über die pathophysiologische Bedeutung bestimmter Neurotransmittersysteme bei psychischen Störungen.

Die vorliegende Übersicht soll einige wichtige Befunde pharmakologischer und biochemischer Untersuchungen darstellen und anhand ausgewählter Beispiele einen kurzen Einblick in das faszinierende Gebiet biologisch-psychiatrischer Forschung geben.

Schlüsselwörter

Neurotransmitter-Rezeptoren Funktionsstörungen-Depression-Schizophrenie-Angst 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aktories K (1985) Molekulare Wirkungsmechanismen von Antidepressiva. In: Philipp M (Hrsg) Grundlagen und Erfolgsvorhersage der ambulanten Therapie mit Antidepressiva. Springer, Berlin Heidelberg New York, pp 1–16CrossRefGoogle Scholar
  2. 2.
    Asberg M, Träskman L, Thoren P (1976) 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry 33:1193–1197PubMedCrossRefGoogle Scholar
  3. 3.
    Barbaccia ML, Costa E, Ferrero P, et al. (1986) Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: Studies in depression, schizophrenia, and Alzheimer’s disease. Arch Gen Psychiatry 43:1143–1147PubMedCrossRefGoogle Scholar
  4. 4.
    Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie, 4. Aufl. (unter Mitarbeit von H Wetzel). Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  5. 5.
    Berridge MJ (1985) Die Signalübertragung in der Zelle. Spektrum der Wissenschaft: 136–146Google Scholar
  6. 6.
    Bogerts B, Meertz E, Schönfeldt-Bausch R (1985) Basal ganglia and limbic system pathology in schizophrenia: a morphometric study. Arch Gen Psychiatry 42:784–791PubMedCrossRefGoogle Scholar
  7. 7.
    Bondy B, Ackenheil M, Elbers R, Fröhler M (1985) Binding of 3H-spiperone to human lymphocytes: A biological marker in schizophrenia? Psychiatry Res 15:41–48PubMedCrossRefGoogle Scholar
  8. 8.
    Bowery NG, Price GW, Hudson AL, et al. (1984) GABA receptor multiplicity. Visualization of different receptor types in the mammalian CNS. Neuropharmacology 23:219–231PubMedCrossRefGoogle Scholar
  9. 9.
    Charney DS, Heninger GR (1986) Abnormal regulation of noradrenergic function in panic disorders. Arch Gen Psychiatry 43:1042–1054PubMedCrossRefGoogle Scholar
  10. 10.
    Charney DS, Heninger GR, Sternberg DE (1982) Failure of chronic antidepressant treatment to alter growth hormone response to Clonidine. Psychiatr Res 7:135–138CrossRefGoogle Scholar
  11. 11.
    Cooper JR, Bloom FE, Roth RH (1986) The biochemical basis of neuropharmacology, 5th ed. Oxford University Press, New YorkGoogle Scholar
  12. 12.
    Corn TH, Thompson C, Checkley SA (1984) Effects of desipramine treatment upon central adrenoceptor function in normal subjects. Br J Psychiatry 145:139–145PubMedCrossRefGoogle Scholar
  13. 13.
    Costa E, Guidotti A (1985) Endogenous ligands for benzodiazepine recognition sites. Biochem Pharmacol 34:3399–3403PubMedCrossRefGoogle Scholar
  14. 14.
    Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cholinergic innervation of cortex. Science 219:1184–1190PubMedCrossRefGoogle Scholar
  15. 15.
    Crawley JCW, Crow TJ, Johnstone EC, et al. (1986) Dopamine D receptors in schizophrenia studied in vivo. Lancet 11:224–225CrossRefGoogle Scholar
  16. 16.
    Cross AJ, Crow TJ, Ferrier IN, et al. (1983) Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J Neural Transm 18:265–272Google Scholar
  17. 17.
    Crow TJ (1985) The two-syndrome concept: origine and current status. Schizophrenia Bull 11:471–485CrossRefGoogle Scholar
  18. 18.
    Crow TJ, Owens F, Cross AJ, et al. (1981) Neurotransmitter enzymes and receptors in post-mortem brain in schizophrenia: Evidence that an increase in D2 receptors is associated with the type I syndrome. In: Riederer P, Usdin E (eds) Transmitter biochemistry of human brain tissue. Macmillan, London, pp 85–96Google Scholar
  19. 19.
    Dilsaver SC (1986) Cholinergic mechanisms in depression. Brain Res Rev 11:285–316CrossRefGoogle Scholar
  20. 20.
    Dolin S, Little H, Hudspith M, et al. (1987) Increased dihydropyridine-sensi-tive channels in rat brain may underlie ethanol physical dependence. Neuropharmacology 26:275–279PubMedCrossRefGoogle Scholar
  21. 21.
    Dorow R, Horowski R, Paschelke G, et al. (1983) Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet II: 98–99CrossRefGoogle Scholar
  22. 22.
    Enna SJ, Möhler H (1986) γ-Aminobu-tyric acid (GABA) receptors and their association with benzodiazepine recognition sites. In: Meltzer HY (ed) Psychopharmacology: The third generation of progress. Raven Press, New York, pp 265–272Google Scholar
  23. 23.
    Gold MS, Rea WS (1983) The role of endorphines in opiate addiction, opiate withdrawal and recovery. Psych Clin North Am 6:489–520Google Scholar
  24. 24.
    Haefely W (1983) The biological basis of benzodiazepine actions. J Psychoactive Drugs 15:19–39PubMedCrossRefGoogle Scholar
  25. 25.
    Holsboer F, Benkert O (1985) Neu-roendokrinologische und endokrino-logische Forschung bei depressiven Patienten. Nervenarzt 56:1–11PubMedGoogle Scholar
  26. 26.
    Johnstone EC, Crow TJ, Frith CD, et al. (1976) Cerebral ventricular size and cognitive impairment in schizophrenia. Lancet 11:924–926CrossRefGoogle Scholar
  27. 27.
    Laakmann G, Schumacher G, Benkert O, et al. (1977) Stimulation of growth hormone secretion by desipramin and chlorimipramin in man. J Clin Endocrinol Metabol 44:1010–1013CrossRefGoogle Scholar
  28. 28.
    Langer SZ, Raisman R (1983) Binding of (3H)imipramine and (3H)desipra-mine as biochemical tolls for studies in depression. Neuropharmacology 22: 407–413PubMedCrossRefGoogle Scholar
  29. 29.
    Lloyd KG, Thuret F, Pilc A (1986) GABA and the mechanism of action of antidepressant drugs. In: Bartholini G, Lloyd KG, Morselli P (eds) GABA and mood disorders. Experimental and clinical research. Raven Press, New York, pp 33–42Google Scholar
  30. 30.
    Lundberg JM, Hökfelt, T (1983) Coexistence of peptides and classical neurotransmitters. Trends Neurosci 6:325–333CrossRefGoogle Scholar
  31. 31.
    Mann JJ, McBride PA, Stanley M (1987) Postmortem monoamine receptor and enzyme studies in suicide. Ann NY Acad Sci 487:114–121CrossRefGoogle Scholar
  32. 32.
    Matussek N, Ackenheil M, Hippius H, et al. (1980) Effect of Clonidine on growth hormone release in psychiatric patients. Psychiatr Res 2:25–36CrossRefGoogle Scholar
  33. 33.
    Meltzer HY, Lowy MT (1987) The serotonin hypothesis of depression. In: Meltzer HY (ed) Psychopharmacology: The third generation of progress. Raven Press, New York, pp 513–526Google Scholar
  34. 34.
    Miles A, Philbrick DRS (1988) Melatonin and psychiatry. Biol Psychiatry 23:405–425PubMedCrossRefGoogle Scholar
  35. 35.
    Mönier H (1984) Benzodiazepine receptors and their ligands. In: Bowery NG (ed) Actions and interactions of GABA and benzodiazepines. Raven Press, New York, pp 155–166Google Scholar
  36. 36.
    Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, a--adrenergic and histamine receptors to clinical potency. Am J Psychiatry 137:1518–1522PubMedGoogle Scholar
  37. 37.
    Reynolds GP (1983) Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305:527–529PubMedCrossRefGoogle Scholar
  38. 38.
    Richards JG, Schoch P, Mönier H, et al. (1986) Benzodiazepine receptors resolved. Experientia 42:121–126PubMedCrossRefGoogle Scholar
  39. 39.
    Schofield PR, Darlison MG, Fujita N, et al. (1987) Sequence and functional expression of the GABA-A receptor shows a ligand-gated receptor super-family. Nature 328:221–227PubMedCrossRefGoogle Scholar
  40. 40.
    Sibley DF, Lefkowitz RJ (1985) Molecular mechanisms of receptor desensiti-zation using the β-adrenergic receptor coupled adenylate cyclase system as a model. Nature 317:124–129PubMedCrossRefGoogle Scholar
  41. 41.
    Snyder SH (1982) Schizophrenia. Lancet II: 970–974CrossRefGoogle Scholar
  42. 42.
    Starke K (1981) Presynaptic receptors. Annu Rev Pharmacol Toxicol 21:7–30PubMedCrossRefGoogle Scholar
  43. 43.
    Stoof JC, Kebabian JW (1984) Two dopamine receptors: Biochemistry, physiology and pharmacology. Life Sci 35:2281–2296PubMedCrossRefGoogle Scholar
  44. 44.
    Sugrue MF (1983) Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharm Ther 21:1–33CrossRefGoogle Scholar
  45. 45.
    Sulser F (1984) Regulation and function of noradrenaline receptor systems in brain. Psychopharmacological aspects. Neuropharmacology 23:255–261PubMedCrossRefGoogle Scholar
  46. 46.
    Suzdak PD, Glowa JR, Crawley JN, et al. (1986) A selective imidazobenzo-diazepine antagonist of ethanol in the rat. Science 234:1243–1247PubMedCrossRefGoogle Scholar
  47. 47.
    Wetzel H, Heuser I, Benkert O (1987) Stupor and affective state: alleviation of psychomotor disturbances by loraze-pam and recurrence of symptoms after Ro 15–1788. J Nerv Ment Dis 175:240–242PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • H. Wetzel
    • 1
  • O. Benkert
    • 1
  1. 1.Psychiatrische KlinikUniversität MainzMainzDeutschland

Personalised recommendations